Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | LAP3 | P28838 | 4/20 | 0.47 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8578236 | 0.85 | EPHX1 (0.50) | SLC1A3SLC1A2SLC1A1EPHX1ALPI | |
| SCHEMBL2316542 | 0.82 | EPHX1 (0.47) | SLC1A3SLC1A2SLC1A1EPHX1ALPI | |
| SCHEMBL2320960 | 0.82 | EPHX1 (0.47) | SLC1A3SLC1A2SLC1A1EPHX1ALPI | |
| Hydrochloric Acid SCHEMBL5754335 | 0.77 | SRR (0.61) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL4780746 | 0.77 | SRR (0.61) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL901287 | 0.77 | CTRB1 (0.49) | — | |
| SCHEMBL15671356 | 0.77 | TRPM8 (0.50) | EPHX1SRRSIGMAR1 | |
| SCHEMBL27858195 | 0.76 | CYP1A2 (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL295838 | 0.75 | ALPI (0.55) | SLC1A3SLC1A2SLC1A1EPHX1ALPI | |
| SCHEMBL17905254 | 0.75 | MEN1 (0.46) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013072933-A2 | PROCESS FOR PREPARATION OF 2-ACETAMIDO-N-BENZYL-3-METHOXYPROPIONAMIDE | GLENMARK GENERICS LIMITED (IN) | 2013-05-23 | — | — | WO | claimed |
| EP-2534127-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN Laboratories Limited (IN) | 2012-12-19 | — | — | EP | claimed |
| WO-2011099033-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-08-18 | — | — | WO | claimed |
| EP-2914574-A2 | NEW PROCESS | Cambrex Karlskoga Ab (SE) | 2015-09-09 | — | — | EP | disclosed |
| US-8946476-B2 | Process for the preparation of amino acid derivatives | UCB PHARMA GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| WO-2014068333-A2 | NEW PROCESS | CAMBREX KARLSKOGA AB (SE) | 2014-05-08 | — | — | WO | disclosed |
| WO-2013072933-A2 | PROCESS FOR PREPARATION OF 2-ACETAMIDO-N-BENZYL-3-METHOXYPROPIONAMIDE | GLENMARK GENERICS LIMITED (IN) | 2013-05-23 | — | — | WO | disclosed |
| EP-2582833-A1 | ENZYMATIC RESOLUTION OF RACEMIC (2R,S)-2-(ACETYLAMINO)-3-METHOXY-N-(PHENYLMETHYL)PROPANAMIDE | Medichem, S.A. (ES) | 2013-04-24 | — | — | EP | disclosed |
| EP-2352721-B1 | NOVEL PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES | UCB PHARMA GMBH (DE) | 2013-03-27 | — | — | EP | disclosed |
| EP-2534127-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN Laboratories Limited (IN) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011158194-A1 | ENZYMATIC RESOLUTION OF RACEMIC (2R,S)-2-(ACETYLAMINO)-3-METHOXY-N-(PHENYLMETHYL)PROPANAMIDE | MEDICHEM, S.A. (ES) | 2011-12-22 | — | — | WO | disclosed |
| US-20110263899-A1 | Novel Process for the Preparation of Amino Acid Derivatives | UCB PHARMA GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011099033-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-08-18 | — | — | WO | disclosed |
| EP-2352721-A1 | NOVEL PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES | UCB Pharma GmbH (DE) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010052011-A1 | NOVEL PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES | UCB PHARMA, S.A. (BE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2000000463-A1 | ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263899-A1 | Novel Process for the Preparation of Amino Acid Derivatives | BCAT2, DNPEP, NPEPPS | SLC1A3 17/4885SLC1A2 8/4885SLC1A1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.